martes, 6 de noviembre de 2018

STAT Plus: Thousands of sickle cell and hemophilia patients are waiting for gene therapies. Can manufacturers keep up?

Daily Recap

STAT Plus: Thousands of sickle cell and hemophilia patients are waiting for gene therapies. Can manufacturers keep up?

By EMILY MULLIN

ANNIE CAVANAGH/WELLCOME COLLECTION
Gene therapy companies are facing a crucial question: Can they make enough of the viral vectors that ferry repair genes into cells?

No hay comentarios: